- Home
- ACRE vs PRQR Comparison
ACRE vs PRQR Comparison
Compare ACRE & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | PRQR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.9M | 262.5M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACRE | PRQR |
|---|---|---|
| Price | $4.66 | $2.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $5.38 | ★ $7.25 |
| AVG Volume (30 Days) | 471.2K | ★ 972.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.28 | $13.92 |
| P/E Ratio | $3.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.14 | $1.33 |
| 52 Week High | $5.89 | $3.10 |
Technical Indicators
Market Signals| Indicator | ACRE | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 63.66 |
| Support Level | $4.60 | $1.40 |
| Resistance Level | $4.69 | $2.44 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 42.40 | 72.39 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.